A Clinic Specializing in Congestive Heart Failure Has Asked You

A clinic specializing in congestive heart failure has asked you to monitor outcomes on a number of elderly patients. They use both nesiritide and tezosentin and would like your input on these drugs. You can tell them:

A) Tezosentin is an endothelin-receptor dual agonist but has been shown to be ineffective in improving dyspnea or reducing the risk of cardiovascular events.
B) Nesiritide is a recombinant human B-type natriuretic peptide and should not be used in patients with low cardiac filling pressures.
C) Both A and B are correct.
D) A is correct, but B is incorrect. The filling pressure may safely be less than 90mm Hg as long as the patient is continuously monitored.